ArticleBlood advances2020
Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Genetic Variation and Sickle Cell Disease Severity: A Systematic Review and Meta-Analysis.JAMA network open · 2023Pooled it
- Circulating erythropoietin concentration associates with thromboembolism in sickle cell disease.British journal of haematology · 2026Article
- Sickle cell disease: managing thromboembolism.Hematology. American Society of Hematology. Education Program · 2025Review
- Dengue fever uncovers a late diagnosis of sickle cell disease- a case report.BMC infectious diseases · 2025Article
- Understanding and treating menstruation associated sickle cell pain.Contraception and reproductive medicine · 2025Review
- Asymptomatic Acute Cerebral Infarction in a Patient with Hemoglobin Köln.Internal medicine (Tokyo, Japan) · 2024Article
- Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study.Research and practice in thrombosis and haemostasis · 2024Article
- Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.American journal of hematology · 2023Article
- Predisposing Factors and Incidence of Venous Thromboembolism among Hospitalized Patients with Sickle Cell Disease.Journal of clinical medicine · 2023Article
- Modified Blalock-Thomas-Taussig Shunt Using Femoral Artery Homograft.Annals of thoracic surgery short reports · 2023Article
- The Role of Inflammation in The Cellular and Molecular Mechanisms of Cardiopulmonary Complications of Sickle Cell Disease.Biomolecules · 2023Review
- Age- and sex-specific rates of gall bladder disease in children with sickle cell disease.Pediatric blood & cancer · 2022Article
- Exploring the Complex Network of Heme-Triggered Effects on the Blood Coagulation System.Journal of clinical medicine · 2022Article
- Sex as an Independent Risk Factor for Venous Thromboembolism in Sickle Cell Disease: A Cross-Sectional Study.Journal of women's health (2002) · 2022Article
- COVID-19 outcomes in sickle cell disease and sickle cell trait.Best practice & research. Clinical haematology · 2022Review
- P- and E- selectin in venous thrombosis and non-venous pathologies.Journal of thrombosis and haemostasis : JTH · 2022Review
- Thrombomodulin and multiorgan failure in sickle cell anemia.American journal of hematology · 2022Article
- Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study.Journal of clinical medicine · 2022Article
- Predicting risk factors for thromboembolic complications in patients with sickle cell anaemia - lessons learned for prophylaxis.The Journal of international medical research · 2021Article
- NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.Biochemical and biophysical research communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Sickle cell disease (SCD) patients are at a four- to 100-fold increased risk for thrombosis compared with the general population, although the mechanisms and risk factors are not clear. We investigated the incidence and predictors for thrombosis in a retrospective, longitudinal cohort of 1193 pediatric and adult SCD patients treated at our institution between January 2008 and December 2017. SCD diagnosis and thrombotic complications were identified using International Classification of Diseases coding and verified through medical chart review. Clinical and laboratory data were extracted from the medical records. With a median follow-up of 6.4 years, 208 (17.4%) SCD patients experienced 352 thrombotic events (64 strokes, 288 venous thromboembolisms [VTE]). Risk factors for stroke included older age and HbSS/Sβ0-genotype and a lower hemoglobin (Hb) F% in the subset of HbSS/Sβ0-genotype patients (P < .05). VTE risk was independently associated with lower estimated glomerular filtration rate, hydroxyurea (HU) use, HbSS/Sβ0 genotype, and higher white blood cell (WBC) counts and Hb (P ≤ .03). Two thrombomodulin gene variants previously associated with thrombosis in the general African American population, THBD rs2567617 (minor allele frequency [MAF] 0.25; odds ratio [OR], 1.5; P = .049) and THBD rs1998081 (MAF, 0.24; OR, 1.5; P = .059), were associated with thrombosis in this cohort. In summary, thrombotic complications are common, and several traditional and SCD-specific risk factors are associated with thrombotic risk. Future studies integrating clinical, laboratory, and genetic risk factors may improve our understanding of thrombosis and guide intervention practices in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.